Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of
nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.